IO Biotech Stock (NASDAQ:IOBT)
Previous Close
$0.77
52W Range
$0.74 - $2.10
50D Avg
$1.31
200D Avg
$1.48
Market Cap
$49.48M
Avg Vol (3M)
$222.86K
Beta
0.51
Div Yield
-
IOBT Company Profile
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
IOBT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PMVP | PMV Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| IVA | Inventiva S.A. |
| IKNA | Ikena Oncology, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| CSBR | Champions Oncology, Inc. |
| ASLN | ASLAN Pharmaceuticals Limited |
| GLUE | Monte Rosa Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| DSGN | Design Therapeutics, Inc. |
| PHVS | Pharvaris N.V. |
| GPCR | Structure Therapeutics Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| HOWL | Werewolf Therapeutics, Inc. |
| PEPG | PepGen Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| PRDS | Pardes Biosciences, Inc. |
| CMPX | Compass Therapeutics, Inc. |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |